Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients.
Karaba AH, Kim JD, Chiang TP, Alejo JL, Sitaras I, Abedon AT, Eby Y, Johnston TS, Li M, Aytenfisu T, Hussey C, Jefferis A, Fortune N, Abedon R, Thomas L, Habtehyimer F, Ruff J, Warren DS, Avery RK, Clarke WA, Pekosz A, Massie AB, Tobian AAR, Segev DL, Werbel WA.
Karaba AH, et al. Among authors: hussey c.
Am J Transplant. 2023 Mar;23(3):423-428. doi: 10.1016/j.ajt.2022.11.002. Epub 2023 Jan 12.
Am J Transplant. 2023.
PMID: 36906295
Free PMC article.